|
| Status |
Public on Oct 18, 2012 |
| Title |
PXN_A_96h |
| Sample type |
RNA |
| |
|
| Source name |
hNT2 differentiation in presence of paraoxon
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: hNT2
treatment: 1 µM paraoxon
|
| Treatment protocol |
Paraoxon (1 µM) and mipafox (5 µM) were applied to cells freshly dissolved in the differentiation medium.
|
| Growth protocol |
Undifferentiated hNT2 cells were cultured in 75 cm2 flasks at the density of 3 x 10 6 cells with 5% heat-inactivated foetal bovine serum (FBS) plus 50 U/ml penicillin and 100 µg/ml streptomycin in Opti-MEM media. After 24 hours and for initiating differentiation, a differentiation medium with 10 µM retinoic acid, 10% of FBS and antibiotics in DMEM-Glutamax was applied during 4 days. The medium was replaced at the beginning of day 3.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA from hNT2 cells previously was purified using the RNeasy Plus kit (Qiagen, Germantown, MD, USA).
|
| Label |
Cy3
|
| Label protocol |
standard Agilent protocol
|
| |
|
| Hybridization protocol |
standard Agilent protocol
|
| Scan protocol |
Scanned with the Agilent G2565BA Microarray Scanner (Agilent)
|
| Description |
Gene expression after treatment with 1 µM paraoxon
|
| Data processing |
The fluorescence intensities on scanned images were extracted and by Agilent Feature Extraction Software (v10.5.1.1). Data preprocessing was performed with the Agi4x44PreProcess R package using quantile normalization and quality filtering.
|
| |
|
| Submission date |
May 18, 2012 |
| Last update date |
Oct 18, 2012 |
| Contact name |
Marco Fabbri |
| E-mail(s) |
fabbri.marco@gmail.com
|
| Organization name |
Università dell'Insubria
|
| Street address |
via dunant 5
|
| City |
Varese (VA) |
| ZIP/Postal code |
21100 |
| Country |
Italy |
| |
|
| Platform ID |
GPL14550 |
| Series (1) |
| GSE38050 |
Genomic and phenotypic alterations of the neuronal-like cells derived from the human embryonal carcinoma stem cells (NT2) caused by exposure to the organophosphorus compounds paraoxon and mipafox |
|
